VANCOUVER, British Columbia, July 06, 2026 (GLOBE NEWSWIRE) -- Cannabix Technologies Inc. (CNSX:BLO.CN) (OTCID:BLOZF) (Frankfurt:8CT.GF) (the “Company” or “Cannabix”) developer of marijuana and alcohol breath testing technologies for workplace safety and law enforcement, announces detection of cocaine and its primary metabolite, benzoylecgonine, in human breath samples tested with the Marijuana Breath Test ("MBT"). Human breath samples were collected using the Cannabix Breath Collection Unit (“BCU”) and were analyzed by Omega Laboratories Inc. ("Omega") utilizing liquid chromatography-mass spectrometry ("LC-MS").
Read more at globenewswire.comThis article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
/Medical%20lab%20microscope%20chemistry%20biology%20test%20by%20Shutter2U%20via%20Adobe%20Stock.jpeg)
/AI%20(artificial%20intelligence)/An%20aerial%20view%20of%20a%20data%20center%20cooling%20system%20by%20Sepia100%20via%20Adobe%20Stock.jpeg)
/Jen-Hsun%20Huan%20NVIDIA's%20Founder%2C%20President%20and%20CEO%20by%20jamesonwu1972%20via%20Shutterstock.jpg)
